On December 10th, the “2021 Annual Conference of the Ophthalmology Management Sub-Committee of Guangdong Medical Industry Association,” organized by the Guangdong Medical Industry Association, was successfully held in Foshan. The conference brought together members of the ophthalmology sub-committee of the industry association in Guangdong Province and professionals in the field of ophthalmology from both within and outside the province. They shared and exchanged information on hot topics in ophthalmology, new advancements in ophthalmic medical technology, ophthalmic clinical practices, and basic research. The aim was to promote the development of the medical industry, enhance the level of ophthalmic diagnosis and treatment technology, and explore new discoveries and future development trends in ophthalmic clinical practices.
Big Vision Medical Technology has always focused on the research and application of AI in ophthalmology. Professor Chen Xinjian, the founder, was invited to participate in this ophthalmology annual conference and delivered a presentation on the topic of “AI Diagnosis of Ophthalmic OCT Images.” He showcased Big Vision’s independent innovation capabilities and the assistance that their medical imaging AI technology brings to clinical practices. It also allowed everyone to experience the advancements of AI technology in the field of retinal disease diagnosis.
With the intensifying aging population and changes in the spectrum of blinding eye diseases in China, age-related, metabolic, and highly myopic-related retinal diseases have become the leading causes of irreversible blindness, accounting for 54.7% of all blind patients. In addition to factors such as increased stress from modern life, work, and study, improper eye use, and changing lifestyle habits, there is a large population of individuals with eye diseases. However, there is a significant imbalance and inadequacy in China’s ophthalmic medical resources.
Artificial intelligence, as a new generation of innovative technology, is an effective approach to address this problem. Big Vision unveiled its independently developed fully automated AI OCT BV1000 at the conference, bringing together numerous ophthalmic experts and doctors to share the latest research achievements in the field of assisted diagnosis of eye diseases.
During the exhibition, Big Vision’s booth attracted many experts who were interested in the equipment and came to experience it. Through close contact with the BV1000 device, they personally experienced its “intelligent, precise, and efficient” capabilities in ophthalmic examinations. With automatic pupil positioning and focusing, as well as comprehensive voice guidance, the device can complete an examination of both eyes for a patient in an average of 2 minutes. It integrates a leading ophthalmic image AI analysis system capable of assisting in the analysis of 16 major eye diseases, including choroidal neovascularization, macular edema, macular holes, and epiretinal membranes.
The diagnostic results can be synchronously sent to mobile devices through a cloud platform. The BV1000 device’s convenient operation and powerful AI-assisted diagnostic function effectively address the pain points of imbalanced primary ophthalmic medical resources. It received unanimous praise from the attending experts at the exhibition.
As a pioneer in ophthalmic image AI analysis and diagnosis in China, Big Vision will continue to adhere to its corporate mission of “early detection of every problematic eye and providing the best treatment plan”. We will utilize AI to empower ophthalmic diagnosis and treatment, and make unremitting efforts to achieve universal eye health.
No comments yet.